Literature DB >> 18629788

Serum calcitonin-negative medullary thyroid carcinoma: role of CgA and CEA as complementary markers.

L Giovanella1, S Crippa, L Cariani.   

Abstract

The biochemical activity of medullary thyroid carcinoma (MTC) includes production of calcitonin (CT), chromogranin A (CgA) and carcinoembryonic antigen (CEA). Routine CT measurement has been proposed as part of the initial evaluation of thyroid nodules and its use could ultimately decrease the morbidity and mortality of MTC. We report on a 43-year-old female patient with a large MTC expressing CT, CgA and CEA on immunostains but with negative preoperative CT and CgA results. Serum CEA was slightly increased and its rapid disappearance predicted radical cure by surgery as confirmed by 2-year follow-up. Our report illustrates that a diagnosis of MTC cannot always be excluded by negative preoperative CT. Fine-needle aspiration with cytomorphological analysis and complementary immunocytochemistry remains an essential diagnostic tool. Finally, serum aliquots must be stored before thyroid surgery in order to measure circulating forms of complementary markers found by tissue immunostaining (CEA and CgA).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18629788     DOI: 10.1177/172460080802300212

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   3.248


  8 in total

Review 1.  Thyroid and parathyroid surgery in pregnancy.

Authors:  Randall P Owen; Katherine J Chou; Carl E Silver; Yaakov Beilin; Jian J Tang; Robert T Yanagisawa; Alessandra Rinaldo; Ashok R Shaha; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-09-28       Impact factor: 2.503

2.  Resveratrol induces Notch2-mediated apoptosis and suppression of neuroendocrine markers in medullary thyroid cancer.

Authors:  Matthew Truong; Mackenzie R Cook; Scott N Pinchot; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Ann Surg Oncol       Date:  2010-12-24       Impact factor: 5.344

3.  Disparity between tissue and serum calcitonin and carcinoembryonic antigen in a patient with medullary thyroid carcinoma.

Authors:  Daisy V Alapat; Kenneth B Ain; David A Sloan; Kristin G Monaghan; Rouzan G Karabakhtsian
Journal:  Endocrine       Date:  2011-01-18       Impact factor: 3.633

Review 4.  Clinical challenges with calcitonin-negative medullary thyroid carcinoma.

Authors:  Maria Teresa Samà; Ruth Rossetto Giaccherino; Marco Gallo; Francesco Felicetti; Francesca Maletta; Nadia Bonelli; Alessandro Piovesan; Nicola Palestini; Ezio Ghigo; Emanuela Arvat
Journal:  J Cancer Res Clin Oncol       Date:  2016-04-28       Impact factor: 4.553

5.  Calcitonin-negative neuroendocrine tumor of the thyroid with metastasis to liver-rare presentation of an unusual tumor: A case report and review of literature.

Authors:  Huai-Jie Cai; Han Wang; Nan Cao; Bin Huang; Fan-Lei Kong; Li-Ren Lu; Ya-Yuan Huang; Wei Wang
Journal:  World J Clin Cases       Date:  2020-01-06       Impact factor: 1.337

Review 6.  Current understanding and management of medullary thyroid cancer.

Authors:  Madhuchhanda Roy; Herbert Chen; Rebecca S Sippel
Journal:  Oncologist       Date:  2013-09-13

Review 7.  Medullary thyroid carcinoma with double negative calcitonin and CEA: a case report and update of literature review.

Authors:  Claudio Gambardella; Chiara Offi; Guglielmo Clarizia; Roberto Maria Romano; Immacolata Cozzolino; Marco Montella; Rosa Maria Di Crescenzo; Massimo Mascolo; Angelo Cangiano; Sergio Di Martino; Giancarlo Candela; Giovanni Docimo
Journal:  BMC Endocr Disord       Date:  2019-10-16       Impact factor: 2.763

8.  Serum Calcitonin-Negative Medullary Thyroid Carcinoma: A Case Series of 19 Patients in a Single Center.

Authors:  Sun Jung Kim; Hyeok Jun Yun; Su-Jin Shin; Yong Sang Lee; Hang-Seok Chang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-05       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.